Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.

As of March 31, 2009, Optimer held cash, cash equivalents and short-term investments of $62.6 million.

"We are off to a strong start in 2009," said Michael N. Chang, Ph.D., Optimer's President and CEO. "We announced plans to prepare a marketing application in Europe based on the results of the first fidaxomicin Phase 3 trial for Clostridium difficile infection. We also reported positive top-line results from the second prulifloxacin Phase 3 trial for the treatment of infectious diarrhea."

Recent Corporate Highlights

  • Announced plans to prepare a Marketing Authorization Application (MAA) for submission with the European Medicines Agency (EMEA) for approval of fidaxomicin as an oral treatment for Clostridium difficile infection (CDI) based on the results from the Company's first Phase 3 fidaxomicin trial.
  • Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
  • Announced positive results from the second pivotal Phase 3 trial of prulifloxacin for the treatment of infectious diarrhea. The tri
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Clinverse, Inc. ... for clinical trials, announced today it has formed ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates ... SpendMD ™, Aggregate Spend Solutions’ recently-launched ... tracking and reporting transfer of value at investigator ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Many have ... as contributor to acne. Recently physicians from Clinical ... mental stress on the skin, and suggested using ... reduce the chemicals produced from stress that cause acne. ... the negative feelings acne brings about, stress causes changes ...
(Date:5/21/2013)... May 21, 2013  Personal Genome Diagnostics Inc. ... proprietary methodologies and expertise in genomic analysis of ... in collaboration with Blueprint Medicines.  PGDx is an ... genomic alterations in tumors, and Blueprint Medicines is ... for a genetically defined patient population. ...
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... of conventional and current solar cells include high production ... rely on toxic and scarce materials. Northwestern University researchers ... will minimize all of these solar energy technology limitations. ... solve the problem of the Grtzel cell, a promising ...
... JOSE, Calif., May 23, 2012  Ariosa Diagnostics, a molecular ... that provides more information on the factors which may ... blood. The study was led by Professor Kypros Nicolaides, ... at King,s College Hospital in the United Kingdom. ...
... May 23, 2012 Reportlinker.com announces that ... in its catalogue: ... Nanocrystals http://www.reportlinker.com/p0799333/Nanotechnology-for-Drug-Delivery-Global-Market-for-Nanocrystals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... a $136 billion nanotechnology-enabled drug delivery market ...
Cached Biology Technology:Taking solar technology up a notch 2Taking solar technology up a notch 3Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women 2Nanotechnology for Drug Delivery: Global Market for Nanocrystals 2Nanotechnology for Drug Delivery: Global Market for Nanocrystals 3Nanotechnology for Drug Delivery: Global Market for Nanocrystals 4Nanotechnology for Drug Delivery: Global Market for Nanocrystals 5Nanotechnology for Drug Delivery: Global Market for Nanocrystals 6Nanotechnology for Drug Delivery: Global Market for Nanocrystals 7Nanotechnology for Drug Delivery: Global Market for Nanocrystals 8Nanotechnology for Drug Delivery: Global Market for Nanocrystals 9
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... Northwestern University researchers have developed a new method ... temporary holes in the cell surface. The technique ... and related biological fields. , Bulk electroporation ... through reversible nanopores in the cell membrane that ... is an increasingly popular method of cell ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2
... LONDON, April 12, 2012 - - ... M2SYS Biometrics Product Portfolio - - Hitachi ... entered into a strategic partnership making M2SYS Hitachi,s primary Value ... Vein scanner. Biometric Finger Vein identity management scanning ...
... sea grass along the subtropical Florida coast, manatees would seem ... can injure the mammals, sometimes shattering their ribcages or leaving ... and Aquarium, USA, explains that many factors put manatees at ... vulnerable to human activity. For more than 14 years, Mote ...
... historically been driven by a demand-side mindset attempting ... permits, taxation, and multi-national climate change treaties. However, new ... University suggests that actually buying coal, oil and other ... be a far better way to fight climate change. ...
Cached Biology News:M2SYS Technology Partners with Hitachi to Offer Innovative Biometric Finger Vein Scanner to US Market 2Manatee hearing good enough to sense approaching motorboats 2Manatee hearing good enough to sense approaching motorboats 3Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change 2
... CELSR3 is an Orphan-U GPCR with ... is expressed during development at sites of active ... brain, spinal cord, dorsal root ganglion, and eye. ... brain, colon, heart/melanocyte/uterus, lung, nerve, and placenta libraries. ...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
Biology Products: